Author: James Love

This was the title the Washington Post today gave the AP story.

This was the title of the FTC Press release:

Continue Reading →

Today I am at Harvard, attending a workshop titled: Unbranding Medicines: the politics, promise, and challenge of generic drugs. This is put on by the Harvard Interfaculty Initiative on Medicines and Society. The program in general is quite impressive, particularly as regards to the depth of experience and knowledge about the generic drug industry, including its early origins.

I was asked to speak about the use of prizes. The slides from my presentation are here:

Continue Reading →

This is from an exchange on IP-Health.

———–
Dear Aidan and Thomas.

There are several things I could mention about this revised position on compulsory licenses, but I will begin with these.

Continue Reading →

This is a comment on the references to compulsory licensing in the Hollis/Pogge HIF book that are quoted below.

https://www.keionline.org/blogs/2008/11/18/excerpts-from-hif-compulsory-licensing/
Aidan Hollis and Thomas Pogge, The Health Impact Fund, Making New Medicines Accessible for All, A Report of Incentives for Global Health, 2008.

Continue Reading →

On November 25, 2008, I was invited to give a talk in Vienna, at the meeting of the Chamber of Commerce (the WKO). The event was organized by Eva Lichtenberger, a Green Party MEP. Eva also spoke, and gave a great talk, in German. Her slides were in English, and I’ll add them when I can. The outline of my talk is given below.

Continue Reading →

On November 25, 2008, I was invited to give a talk in Vienna, at the meeting of the Chamber of Commerce (the WKO). The event was organized by Eva Lichtenberger, a Green Party MEP. Eva also spoke, and gave a great talk, in German. Her slides were in English, and I’ll add them when I can. The outline of my talk is given below.

Continue Reading →

KEI has filed comments on the EC’s Green Paper on Copyright limitations and exceptions. They are on the web here: https://www.keionline.org/index.php?option=com_content&task=view&id=215

Continue Reading →

UNCTAD head Supachai Panitchpakdi will open up this December 16-19 event in Bangkok. The meeting is funded by the Federal Ministry for Economic Cooperation and Development (BMZ), Germany.

Programme Events

Event: Symposium on Flexibilities in International Intellectual Property Rules and Local Production of Medicines
Date: 16–19 December 2008

Location: Bangkok, Thailand
Venue: Conference Room of Arnoma Hotel
Description:

Continue Reading →

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”

Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Continue Reading →

In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:

Continue Reading →